RxDoctor Payments Data

Elizabeth Hereford, MD

Cardiovascular Disease · Lodi, CANPI 1710012117

Payments from drug & device makers

$3,393in general payments, 2019–2025

Across 172 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$503
  • Johnson & Johnson$496
  • AstraZeneca$390
  • Novartis$350
  • Pfizer$344
  • Merck$293
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,36599%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,393 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$134,578
Medicare patients
379
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$327,864
JardianceEmpagliflozin44$53,326
XareltoRivaroxaban41$41,903
Repatha SureclickEvolocumab41$37,750
EntrestoSacubitril/Valsartan27$29,782
FarxigaDapagliflozin Propanediol26$16,039
Atorvastatin Calcium450$4,377
Metoprolol Succinate218$3,424
Potassium Chloride60$2,597
Digoxin74$2,287
Ezetimibe92$1,985
Losartan Potassium191$1,983
Amlodipine Besylate229$1,859
Hydralazine Hcl61$1,495
Rosuvastatin Calcium92$1,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$344$327,864318 claims
Boehringer IngelheimJardiance$503$53,32644 claims
Johnson & JohnsonXarelto$496$41,90341 claims
NovartisEntresto$350$29,78227 claims
AstraZenecaFarxiga$390$16,03926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →